Peers

Glaxosmithkline Pharmaceuticals Ltd. stands out among its peers with strong profitability metrics, particularly in ROE and EPS growth. While some competitors exhibit higher revenue growth, GSK maintains a solid balance of growth and profitability, positioning it well within the pharmaceuticals sector.

• • GlaxoSmithKline leads in ROE and EPS growth, indicating strong profitability.
• • Mankind Pharma shows impressive revenue growth but is slightly overvalued at its current PE ratio.
• • Divi's Laboratories is facing significant challenges with declining revenue growth over the past three years.
• • Cipla is undervalued compared to its peers with a low PE and strong revenue growth.

• • Glaxosmithkline Pharmaceuticals Ltd.: Highest ROE (33.43%) and strong EPS growth (54.76) indicate robust profitability.
• • Cipla Ltd.: Strong revenue growth (YoY: 13.28%) and low valuation multiples (PE: 23.73) make it a value pick.
• • Dr. Reddy's Laboratories Ltd.: Solid profitability with high ROE (21.76%) and low PE (15.50) suggest good value.